Targeting p35/Cdk5 Signalling via CIP-Peptide Promotes Angiogenesis in Hypoxia by Bosutti, A et al.
Targeting p35/Cdk5 Signalling via CIP-Peptide Promotes
Angiogenesis in Hypoxia
Alessandra Bosutti1, Jie Qi1, Roberta Pennucci2, David Bolton3, Sabine Matou1, Kamela Ali1, Li-Huei
Tsai4,5, Jerzy Krupinski1,6, Eugene B. Petcu7, Joan Montaner8, Raid Al Baradie9, Francesca Caccuri10,
Arnaldo Caruso10, Giulio Alessandri11, Shant Kumar1,12, Cristina Rodriguez13, Jose Martinez-Gonzalez13,
Mark Slevin1,7*
1 School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom, 2 Cell Adhesion Unit, Department of Neuroscience Dibit-
Istituto Scientifico San Raffaele, Milano, Italy, 3 Chip-Man Technologies Ltd, Tampere, Finland, 4 Howard Hughes Medical Institute, Massachusetts Institute of
Technology Picower Institute for Learning and Memory, Cambridge, Massachusetts, United States of America, 5 Stanley Centre for Psychiatric Research, Broad
Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, United States of America, 6 Hospital Universitari Mútua
de Terrassa, Department of Neurology, Barcelona, Spain, 7 Griffith University School of Medicine, Gold Coast Campus, Griffith University, Southport, Australia,
8 Neurovascular Research Laboratory, Vall De’Hebron University Hospital, Barcelona, Spain, 9 College of Applied Medical Science, Almajmaah University,
Almajmaah, Kingdom of Saudi Arabia, 10 University of Brescia, Section of Microbiology, Department of Experimental and Applied Medicine, Medical School,
Brescia, Italy, 11 Fondazione Istituto di Ricovero e Cura Carattere Scientifico Neurological Institute "Carlo Besta", Cellular Neurobiology Laboratory, Department
of Cerebrovascular Diseases, Milan, Italy, 12 Department of Pathological Sciences, Manchester University and Christie Hospital, Manchester, United Kingdom,
13 Centro de Investigacion Cardiovascular, Hospital de la Santa Creu i Sant, Pau, Barcelona, Spain
Abstract
Cyclin-dependent kinase-5 (Cdk5) is over-expressed in both neurons and microvessels in hypoxic regions of stroke
tissue and has a significant pathological role following hyper-phosphorylation leading to calpain-induced cell death.
Here, we have identified a critical role of Cdk5 in cytoskeleton/focal dynamics, wherein its activator, p35, redistributes
along actin microfilaments of spreading cells co-localising with p(Tyr15)Cdk5, talin/integrin beta-1 at the lamellipodia in
polarising cells. Cdk5 inhibition (roscovitine) resulted in actin-cytoskeleton disorganisation, prevention of protein co-
localization and inhibition of movement. Cells expressing Cdk5 (D144N) kinase mutant, were unable to spread,
migrate and form tube-like structures or sprouts, while Cdk5 wild-type over-expression showed enhanced motility and
angiogenesis in vitro, which was maintained during hypoxia. Gene microarray studies demonstrated myocyte
enhancer factor (MEF2C) as a substrate for Cdk5-mediated angiogenesis in vitro. MEF2C showed nuclear co-
immunoprecipitation with Cdk5 and almost complete inhibition of differentiation and sprout formation following siRNA
knock-down. In hypoxia, insertion of Cdk5/p25-inhibitory peptide (CIP) vector preserved and enhanced in vitro
angiogenesis. These results demonstrate the existence of critical and complementary signalling pathways through
Cdk5 and p35, and through which coordination is a required factor for successful angiogenesis in sustained hypoxic
condition.
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Introduction
The importance of angiogenesis in relation to neuronal
replenishment and survival after stroke has been clearly
demonstrated. In this respect, revascularization and associated
reperfusion are vital determinants of tissue survival and patient
recovery after stroke and therefore a major potential target for
successful therapies [1]. Angiogenesis “per se” is a tightly
regulated multi-step process, by which new blood vessels are
formed from endothelial cell (EC) sprouts, emanating from pre-
existing vessels and is mediated by the combination of a
complex range of angiogenic and anti-angiogenic factors,
driving the recruitment, migration, proliferation and
differentiation of ECs [2]. Effective angiogenesis is strictly
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dependent on the proper spatial and temporal control of focal
adhesions and activation of cytoskeletal organizers that
regulate cell mechanical forces and the cell plasticity during
migration, sprouting and cell differentiation within developing
neo-capillary structures [3]. Beyond the typical canonical
signalling molecules already characterized, a set of cyclin-
dependent kinases (Cdks), has been shown to contribute
significantly to the angiogenic response [4]. Among them, the
Cdk5 is emerging as a potential important regulator of
vasculogenesis [5].
Cdk5 is a proline-directed serine/threonine kinase highly
expressed in the central nervous system. Initially due to the
prevalence of its activity and activators (p35, p25 and p39) in
neuronal cells, Cdk5 was considered as a neuron-specific
kinase, involved in neurite outgrowth, neural migration,
synaptic activity, neural cytoskeletal organization and neural
survival [6]. Over the past decade, Cdk5 has been isolated in
various non-neuronal tissues and cells [7], including ECs, and
has been demonstrated to be essential for important cellular
activities, including angiogenesis of Human Umbilical Vein ECs
[5], neuronal cell adhesion and migration [7]; whereas its
aberrant activation has been associated directly with neuronal
cell death [8].
Increased expression of Cdk5 and of both p35 and p25
activators has been reported in human stroke [9,10] and after
focal middle cerebral artery occlusion [8]. After brain ischemia,
the rise in neuronal death is crucially associated by the Cdk5
hyper-activation mediated by p25 [8,9]. The excitotoxic signal
transduction cascade induced by hypoxia leads to excessive
activation of calpains, a group of calcium-activated cytosolic
proteases, that cleave p35 to more stable p25 peptide, with the
following Cdk5 hyperactivation and neuronal apoptosis;
whereas modulation of p35 amount and its binding with Cdk5
confers cytoprotection [11,12]. Additionally, in our previous
work, we have shown over-expression of Cdk5 together with
p35/p25 in apoptotic brain ECs in hypoxic regions of stroked
tissue [10]. We have shown the up-regulation and/or nuclear
translocation of Cdk5 and p35 in neurons and ECs subjected to
oxygen-glucose deficiency and their association with cellular
damage as response to hypoxic conditions therefore, it is
hypothesized that the Cdk5/p35 pathway may be a key
pathophysiological determinant of ECs survival and ultimately
outcome after infarction [13,10].
Currently, research focused on novel therapies directed to
enhance angiogenesis, neurogenesis and improve neurologic
function has highlighted the pharmacological inhibition of
Cdk5/p25 signalling as a novel potential intervention point for
cell protection and improved tissue remodelling after stroke
[13,12]. However, since the use of some inhibitors would
appear to affect also the physiological function of Cdk5 (i.e.
Roscovitine [14]) and/or the regulation of synaptic plasticity (i.e.
calpain inhibitors [15]), their introduction could lead to serious
secondary side effects and thereby compromise any
therapeutic efficacy [13]. Thus, identification and
characterization of novel selective inhibitors of Cdk5/p25
signaling might produce a more viable potential therapeutic
target [12] with particular emphasis to re-vascularization of the
brain tissue [13].
Recently, the neuronal cyto-protective potential of a natural
small peptide (CIP-peptide) was demonstrated after neurotoxic
stress. CIP is a derived-p35 cleavage peptide, which
selectively targets Cdk5/p25 activity without affecting Cdk5/p35
signalling [16], suggesting that CIP may represent a novel
selective vascular protector/stimulator in hypoxic conditions
such as those encountered after stroke.
In this study, we provide crucial evidence for a critical role of
Cdk5 operating through distinct signalling mechanisms in the
co-ordinated and sequential stimulation of cell spreading (actin
fibres, talin and integrin-β-1) and tube differentiation and
sprouting (MEF2C). Furthermore, we show that specific
manipulation of Cdk5 signalling via administration to brain ECs
of the CIP-peptide, allowed enhancement of in vitro cell
migration with production of mature sprouts and tubes.
Therefore, p35/Cdk5 manipulation may represent a novel
strategy for EC protection in response to ischaemic conditions.
Materials and Methods
Cell culture and treatment with Roscovitine
Immortalized (hCMEC/D3) human brain microvascular EC
cells (hBMEC; [17]), were kindly donated by Prof. Babette
Weksler (Division of Haematology and Medical Oncology, Weill
Medical College of Cornell University, New York). Cells were
cultured on type I rat tail collagen (BD Bioscence Pharma, UK)
coated plates, using microvascular EC medium-2 (EBM-2) from
Clonetics (Lonza, Germany), supplemented with growth factors
as recommended by the manufacturer. The concentration
range (2.5-100µM) of (R)-roscovitine (Calbiochem, UK) were
chosen based on other previously published studies
demonstrating effectiveness [5]. 24h of incubation with
roscovitine (50 µM) was found to be optimal for the study. The
effects of (R)-roscovitine on cell proliferation (72h) were
analysed using the CellTiter 96® AQueous One Solution Cell
Proliferation Assay (MTS) (Promega Corporation, USA).
Nuclear membrane damage and activation of cell apoptosis
were evaluated by nuclear inclusion of propidium iodide
counterstained with Hoechst 33258 (Sigma-Aldrich, Germany),
and Quantikine® kit (R&D, USA) for active caspase-3 and
DuoSet IC® kit (R&D, USA) for active p53, respectively. Cell
treatment with staurosporine (Sigma-Aldrich), (0.5-1 µM) was
used as positive control for apoptosis and cell damage
analysis. Appropriate amounts of DMSO, the roscovitine
vehicle, were used to ensure that the effects were roscovitine-
specific.
Cdk5-wt and Cdk5 kinase mutant stable transfections
Stable hBMEC transfectants for the wild type human Cdk5
(Cdk5-wt) or dominant-negative Cdk5 (N144) kinase inactive
mutant (Cdk5-DN) were obtained from pcDNA3-cdk5GFP or
pcDNA3-dnCDK5 expression vectors (Addgene, USA), using
TransIT-2020 as transfection reagent (Mirus Bio LLC, Madison,
USA). pcDNA3-GFP plasmid was used as a negative control
(Addgene, USA). EGM-2 medium containing 500 µg/ml
Geneticin (Invitrogene Life Science, UK) was used as selective
media. Transfection efficiency was defined by the presence of
Cdk5/p35 Signalling in Angiogenesis
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GFP fluorescence and Cdk5 protein levels in different cell
passages.
CIP cloning and stable transfections
A modified EGFP-IRES vector containing CIP sequence [16],
(pLV-CIP plasmids), was a kind gift from Prof. Sashi
Kesavapany, National University of Singapore. CIP peptide is
comprised of 126 residues of p35 protein (accession number:
AAH26347.1) spanning from aa 154 to aa 279. CIP-PCR
products from pLV-CIP plasmid, obtained by PCR (forward
primer, TTA GGA TCC TTG CCT GGG TGA GTT TC and
reverse primer, GTC GGA TCC TCA TGG GTC GGC ATT TAT
C) and digested by BamHI (Invitrogen, UK) were then inserted
by ligation into pcDNA3-GFP expression vector. After positive
cloning in DH5α, purified pcDNA3-CIP-GFP vectors were
stable introduced by transfection into hBMECs using
TransIT-2020 transfection reagent (Mirus Bio LLC, Medison,
USA). EGM-2 medium containing 500 µg/ml Geneticin
(Invitrogene Life Science, UK), was used as selective media.
Positive hBMECs clones were detected by GFP fluorescent
signals and by the level of CIP mRNA by RT-PCR. 18S rRNA
(accession number: NM_022551.2) was used as housekeeping
gene (forward primer, TAG AGG GAC AAG TGG CGT TC and
reverse primer, TGT ACA AAG GGC AGG GACT T).
In vitro capillary tubule-like structure formation on
MatrigeTM
The preparation of ECs and MatrigelTM was performed as
described previously [18]. 6x103 cells were added to the
MatrigeTM reduced in growth factors (Becton Dickinson, UK;
prepared according to the supplier’s instructions), in complete
EBM-2 media with or without scalar amount of tested
compound. The cells were incubated for 24-72 h at 37°C.
DMSO (vehicle) alone, at the same concentration as in the test
samples, was also added in a group of controls in all
experiments. The number of closed tubes was counted with a
Nikon inverted microscope. All experiments were performed in
triplicate.
Spheroid based in vitro angiogenesis assay
The preparation of EC spheroids was performed as
described previously [19,20]. Briefly, cells were harvested from
sub-confluent monolayer cultures by trypsinization and 6x105
cells were suspended in EGM-2 mixed with DMEM (Lonza,
Germany) 10% FBS and 0.25% (w/v) carboxymethylcellulose
(Sigma, UK). Cells were then seeded into non-adherent round-
bottom 96-well plates to assemble into a single spheroid within
24 h at 37 °C, 5% CO2. Basic fibroblast growth factor (human
recombinant FGF-2, (BD Bioscience, UK)) was used as
positive control and added at a final concentration of 25 ng/ml.
After 24h, gels were photographed and sprouting was
assessed quantitatively.
Colorimetric adhesion assay
The adhesion assay was performed in a 96-well pre-coated
with collagen type-I and blocked with 2% BSA (w/v PBS) for
120 min at 37°C. Then the plates were heat denatured at 85°C
for 10 min, to block non-specific bindings. As negative control,
well were only coated with PBS. 1x104 cells were seeded in
each well and after 30 min from the seeding the non-adherent
cells removed by washing with PBS. A value of 100%
attachment was estimated by adding the cells to uncoated and
fixed (methanol) plastic, without washing. After washing, 50ml
of substrate solution (3.75mM p-nitrophenyl N-acetyl-β-d-
glucosaminide, Sigma-Aldrich, 0.05M Sodium citrate pH 5.0,
0.25% Triton- X-100) was added to the wells and the plates
incubated overnight at 37°C. After stopping the reaction (50mM
glycine, pH10.4.5 mM EDTA) the optical density of each well
was determined at 490nm using a microplate reader (Multiskan
Ascent, Thermo Life Sciences, UK). DMSO (vehicle) alone, in
the same concentration as was present in the test samples was
also added in a secondary group of controls in all experiments.
Experiments were done in triplicate.
Spreading assay
Cells were placed in a 96-well plate and incubated for 1h.
The plate was pre-treated as described for the colorimetric
adhesion assay. The experiment was stopped by fixing the
cells with cold methanol for 5 min at room temperature. Cells
were then dried and stained with 1% methylene blue in water.
Approximately 100 cells were examined in multiple microscopic
fields. Multiple fields were imaged from each condition. Cells
were classified as spread when flat and the cytoplasm visible
around the entire circumference of the nucleus and un-spread,
when round and without visible cytoplasm. The number of cells
was then expressed as a % of total cells. Experiments were
done in triplicate.
In vitro angiogenesis assay with continuous live cell
imaging
In different experiments, hBMECs, Cdk5-wt, Cdk5-DN,
and/or CIP transfectants, (1-2x104/ml), were added to a 24-well
plate coated with collagen type I, in complete EBM-2 medium
and maintained at 37 °C and 5% CO2 for 24 h to permit the
formation of a confluent monolayer. Monolayer scratch wound
with or without scalar amounts of the tested compound
roscovitine (2-50 µM) was then induced by scoring the
confluent cell monolayer with a sterile pipette tip to leave a
scratch of approximately 0.4–0.5 mm in width. In vitro cell
differentiation in tube like structures was performed seeding the
cells (100,000 cells/ml) in growth media containing or excluding
the roscovitine (50 µM) over a preformed gelled layer of
MatrigelTM. In vitro adhesion, spreading and elongation assays
were performed seeding separately non-confluent cells on to a
collagen pre-coated 24-well tissue plate. Cells were maintained
at 37°C and 5% CO2. The cell migration from the scratched
monolayer and formation of tube like structures were monitored
continuously in real time for 24h and 72h, respectively and cell
adhesion and subsequent spreading for 2 h, using the
automated cell culture Cell-IQ® Continuous Live Cell Imaging
(Chip-Man Technologies Ltd, Finland). Cells were monitored
via the ImagenTM program, and data analysed by AnalyserTM
software. Each experiment was performed in triplicate. Hypoxia
(1% O2, 5% CO2 and N2) experiments were performed using
reduced EBM-2 (0.1% foetal bovine serum) media, with a pre-
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treatment of 24h. DMSO (vehicle) alone, in the same
concentration as was present in the test samples was also
added in a secondary group of controls in all experiments.
Western Blotting
Medium was removed quickly and cells were washed twice
with cold-ice PBS buffer. Then, protein extraction was
performed using ice-cold RIPA buffer in the presence of a
protease and phosphatase inhibitor cocktail. After 30 min of
incubation in ice, total cell lysate was centrifuged at 12,000 g x
20 min at 4°C. Bredford protein assay (Bio-rad, UK) was used
to quantify protein amount in cell lysate. Protein absorbance
was determined at 580 nm using a microplate reader. 30 µg of
protein was loaded and subsequently separated on 10% SDS-
PAGE gel. Protein samples were transferred onto nitrocellulose
membranes (Whatman International Ltd.), stained with amido-
black solution and photographed to verify the equal loading and
the quality of transfer. The membranes were subsequently
incubated 1h with blocking solution (milk 1% in PBS-Tween
buffer pH 7.4). Incubations with the primary antibodies against
human Cdk5, MEF2C, Hsp70 (Abcam, UK), pTyr(15)Cdk5, p35,
integrin beta-1 (Santa Cruz Biotechnology, UK), Cdk2 and
pThr(160)Cdk2 (Calbiochem, UK), talin (Upstate, UK), and anti-
GAPDH (Santa Cruz Biotechnology, UK) were performed with
conditions as recommended by the manufacturers, overnight at
4°C. The membranes were then washed three time with PBS-
Tween buffer before to be incubated with appropriate
horseradish peroxidase conjugated secondary antibodies
(Dako, UK) at room temperature. Protein bands were
visualised using a chemiluminescence detection kit
(Invitrogene Life Science) and protein contents were expressed
as the ratio to GAPDH protein levels (Bio-Rad quantity one
software). Analysis were performed in triplicate.
Confocal and fluorescence microscopical analysis.
hCMEC/D3 cells were added to a glass cover slip coated
with collagen type-I, in a 24-well plate in complete EBM-2
(2.5% fetal bovine serum) medium. After fixing with 4%
paraformaldehyde (w/v in PBS) cell were washed with PBS and
permeabilised with 0.1% Triton X-100 (v/v in PBS). After
blocking with 1% BSA (w/v in PBS) incubations with primary
antibodies against selected proteins were performed with
conditions as recommended by the manufacturers, overnight at
4°C. Secondary antibodies Alexa Fluor 488 goat anti-rabbit
IgG, Alexa Fluor 488 goat anti-mouse IgG, Alexa Fluor 568
anti-rabbit and Alexa Fluor 460 donkey anti goat (Molecular
Probes/Invitrogen) were incubated with conditions as
recommended by the manufacturer. Rhodamine-phalloidin
(Molecular Probes/Invitrogen) was used to stain filamentous
actin (F-actin). Nuclei were stained with Hoechst 33258
solution (Sigma, UK). Samples without primary antibodies were
used as negative controls. Confocal microscopy was performed
with a Leica TCS SPE1000 system and the accompanying
Leica Application Suite Advanced Fluorescence (LAS AF)
software (Leica Microsystems UK Ltd, Milton Keynes, Bucks,
UK). Images were acquired at 1024x1024 pixel resolution.
Cells were pre-treated with roscovitine (50 µM) for 24h or the
appropriate vehicle (DMSO) and then seeded on the plates.
Signal of autofluorescence was tested, including a negative
control antibody (IgG) staining, as well. Experiments were
performed in triplicate.
Cdk5 kinase activity
Cell lysates for immunoprecipitates and kinase assay were
obtained as described for western blotting, in contrast, a
modified RIPA lacking ionic detergent was used. Cdk5 was
immunoprecipitated using protein A-sepharose CL-4B and
incubated in vitro with Histone H1 (Sigma, UK) and [γ-32P] ATP
(Amersham Radiochemicals, UK). Before to start the
immunoprecipitaiton, cell lysate was pre-cleared suing 100 µl of
sepharose-A slurry per ml of cell lysate. The reaction mixture
with Histone H1 was then resolved by SDS-PAGE followed by
autoradiography. Active Cdk5 would result in the appearance
on autoradiography film of a signal at the size of
phosphorylated histone H1. A purified active complex
Cdk5/p35 expressed in Sf21 cells (Millipore, Billerica, USA)
served as a positive control. 2ng of the active complex was
used in the assay. Immunoprecipitate using rabbit anti-goat
antibody (Dako, UK) served as negative controls.
MEF2C siRNAs
Knockdown of MEF2C expression was performed using
Silencer® Select Pre-Designed & Validated siRNA (Applied
Biosystems, Life technologies, USA). SiRNA delivery was
performed using Lipofectamine 2000 (Invitrogene, UK). After
three days of treatment, in selected media (EBM-2 with
reduced FBS and without antibiotics), knockdown efficiency
was tested via protein assay (Western Blotting) and cells used
for in vitro angiogenesis analysis. Silencer® control scrambled
siRNAs was used as a negative control. Assay conditions were
performed as recommended by the manufacturers.
Affymetrix Microarray
Total RNA was isolated using Trizol Reagent, and purified
using the RNeasy Micro Kit (Qiagen, UK). The assay was
performed according to the manufacturer’s instructions.
Concentration and purity was determined using a NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies) and
RNA quality was assessed using Agilent RNA 6000 Nano Kit
and 2100 Bioanalyzer platform (Agilent, USA). The expression
pattern of untranfected cells and several clones from cells
transfected with the empty vector or a dominant negative form
of human Cdk5 were compared by microarray analysis.
Microarrays and cDNA synthesis were performed following the
GeneChip® WT cDNA Synthesis and amplification Kit
(Affymetrix) and following the Affymetrix GeneChip® Whole
Transcript (WT) Sense Target standard protocol [21,22]. The
array data were summarized and normalized with the RMA
algorithm using the Affymetrix Expression Console software.
Statistical analysis was performed using Spotfire DecisionSite
software (Integromics).
Calpain activity
The fluorometric assay was performed according to the
manufacturer’s instructions (Abcam, UK). Cytosolic proteins
Cdk5/p35 Signalling in Angiogenesis
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were specifically extracted without contaminations of cell
membrane and lysosome proteases and preventing auto-
activation of calpain during the extraction procedure according
to the manufacturer’s instructions. Calpain activity was
quantified using a fluorescence microplate reader BMG
Labtech, USA. The fluorometric assay included a positive
control of active calpain I, as well. Data were expressed as
relative fluorescence units. Experiments were performed in
triplicate.
Statistical analysis
All data were expressed as mean ±SD (standard deviation).
P values were calculated using the ANOVA one-way test using
Student’s t-test for unpaired sample led by MS and followed by
the Wilcoxon 2-sample test. Regression analysis was carried
out according to standard methods provided by MS Excel and
to SPSS version 12. Results were considered to be statistically
significant at values of P <0.05.
Results
R-roscovitine is a selective inhibitor of Cdk5 activity in
hBMECs
(R)-roscovitine is a well-recognized anti-neoplastic drug,
carrying out both apoptotic [23] and anti-proliferative [24]
actions with highly selective inhibitory potential on Cdk5 [5],
and Cdk2 activities [25]. To ensure selective inhibition in our
cellular model, we evaluated roscovitine effects on Cdk5
activity and on the protein levels of Cdk5, Cdk2 and activated
pTyr(15) pCdk5 and pThr(160)Cdk2. Cdk5 activity was estimated
by measurement of histone H1 phosphorylation, one of its
targets. The effect of scalar amounts of roscovitine on cell
viability, cell apoptosis and proliferation were also determined.
Roscovitine at the concentration of 50 µM inhibited completely
Cdk5 activity (Figure S1) and reduced significantly Cdk5 and
pCdk5 protein contents (Figure S1), without affecting Cdk2 or
pThr(160)Cdk2 (Figure S1). Roscovitine did not affect cell
viability, proliferation or apoptosis (Figure S2). Cytotoxic effects
were seen at concentrations of 70 µM and greater.
Cdk5 overexpression supports in vitro hBMEC
angiogenesis during hypoxia
Recent observations suggest that apoptosis of neurons after
brain ischemia is strongly associated with Cdk5 hyper-
activation mediated by its activator p25 [9], however, normal
signaling through the Cdk5/p35 complex promotes neuronal
survival, whilst inhibition of normal Cdk5 activity may inhibit
Hif-1α accumulation and concomitantly induce neuronal cell
death [26]. Firstly, we optimized an in vitro model of low oxygen
tension mimicking hypoxia during stroke, wherein hBMEC were
exposed to 24h of low oxygen levels (1%). Hypoxia conditions
were defined on the evidence that in human hypoxic brain
tissue (i.e. after subarachnoid haemorrhage) the partial
pressure of brain tissue oxygen (PtiO2) decreased dramatically
from the normal values of 40 mmHg [27] to <10 mmHg [28].
Considering the conversion of % oxygen to units of mm Hg,
that assumes 100% oxygen equal to 760 mm Hg, our system
was set at 1% of O2 delivery, as previously described [10], to
create a severe hypoxic environment [29].
In our model, the efficiency of hypoxia (Figure S3) was
evidenced by the increased nuclear inclusion of propidium
iodide (Figure S3), increased protein expression of heat shock
protein Hsp70 (Figures S3B and S3F) and activation of calpain
activity (Figure S3E). We found that hypoxia significantly
reduced in vitro angiogenesis in hBMEC, reducing cell
migration, tubule formation and/or cell sprouting. This was
associated with decreased p35 protein content (Figure S3) and
increased p25/p35 ratio (Figure S3), with no evident changes in
Cdk5 expression (Figure S3). To understand the physiological
importance of Cdk5/p35 signalling, Cdk5 activity was then
deregulated using stable transfections of either Cdk5 kinase
inactive mutant -D144N, (Cdk5-DN) or Cdk5 wild-type (Figure
1), and by pharmacological inhibition with roscovitine (Figure
2). The effects of Cdk5 inhibition on temporal and spatial
cellular adaptations were then analysed by functional in vitro
angiogenesis assays and monitored in real time using IQ Live
Cell Imaging.
In normoxia, inhibition of Cdk5 kinase activity with
roscovitine, resulted in a significant loss or inability to form and
maintain potentially viable capillary structures (Figure 2), as
shown by the inhibitory effect on in vitro cell adhesion (Figure
S4), cell distribution between early and late spreading (Figure
2A), cell motility (Figure 2B), to culminate with the loss of EC
tubule branching networks (Figure 2G) and cell sprouts (Figure
2L). Similarly, cells expressing the dominant Cdk5-kinase
mutant D144N (Figure 1) were unable to spread, migrate and
form new capillary structures or sprouts (Figure 1). Cells over-
expressing Cdk5 wild-type (Figure 1) showed enhanced
angiogenesis in vitro, characterized by increased cell motility,
tubule and sprout formation. Noteworthy, in Cdk5-wt the
increased angiogenic activity was accompanied by abnormal
tubule and sprouts organization (smaller and thinner tubes and
sprouts) (Figure 1C), suggesting that enhancing Cdk5 activity
alone may not be a complete solution to allow protection and
functional enhancement of in vitro angiogenesis. During
hypoxia, inhibition of Cdk5 signalling was associated with a
further inhibition of tube-formation beyond that produced by
Cdk5-DN transfectants during normoxia (Figure 1), whereas
cell migration, sprouting and tubule formation, were almost
maintained at control-normoxic levels in the Cdk5-wt (Figure 1),
thus Cdk5 overexpression preserved angiogenesis during in
vitro hypoxia.
pTyr(15)Cdk5 and p35 mobilization are essential for in
vitro brain endothelial cell migration through
association with integrin beta-1 and talin proteins
Cytoskeleton dynamic and focal complex organizations are
crucial determinants for successful angiogenesis. We
hypothesized that Cdk5 inhibition may affect the cell cyto-
architecture and the observed inhibitory effects on
angiogenesis in vitro may be the direct consequence of Cdk5
misplacement from actin and focal complexes. We also
examined the involvement of the Cdk5 substrate, p35 in this
cytoskeletal/focal organization.
Cdk5/p35 Signalling in Angiogenesis
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We found a marked and specific distribution of Cdk5, pCdk5
and p35 with F-actin in all phases of cell motility (Figure 3),
having a precise time-dependent subcellular localization during
spreading phases. Analysis of p35 intracellular localization
determined at different time/stages of cell spreading, showed
us that p35, emanating from the nucleus (Figure 3C), co-
localized with actin stress fibres extending down the fibre from
the nucleus as the cells spread, to culminate in filament tip
expression in late spreading and moving cells (Figure 3C),
suggesting a precise spatial-temporal mechanism linking p35
to stress fibre formation and/or contractility. Of particular note
p35 (Figure 4A), and pCdk5 (Figure 4B), were clustered with
Figure 1.  Consequences of hypoxia and Cdk5 deregulation on in vitro hBMECs angiogenesis.  Phase contrast images
showing the impact of hypoxia (24h 1% O2) and Cdk5 deregulation on cell migration (A), capillary tube formation (B) and spheroid
cell sprouting (C). Assays were performed during 24h of hypoxia and/or normoxia-control condition, in stable hBMECs transfectants
expressing Cdk5 wild-type (Cdk5-wt) and Cdk5 kinase inactive mutant Cdk5-(DN). Empty Vector (EV) transfectants served as
negative controls of transfection. Hypoxia almost completely inhibited in vitro angiogenesis in hBMECs, as seen by the reduction in
cell migration from scratched monolayer (A), tubule like structure formation (B) and/or cell sprouting (C). In normoxia, Cdk5-wt
overexpression showed increased cell migration (A) and tubule formation (B), with an irregular formation of cell sprouts (C and D,
arrows in magnification) which appeared more thin and disorganized, respect the controls. In contrast, Cdk5 kinase mutants (DN)
were not able to migrate (A), to form new capillary structures (B) or sprouts (C, arrows in D). (G) The number of cell sprouts was
markedly reduced. (A) Notably, in vitro angiogenesis was rescued in Cdk5-wt transfectants during hypoxia. (H) MTS assay was
used to show the exclusion of other effects of hypoxia and transfection on cell proliferation. Calculated results are reported in
graphs: E, number of living cells in wound area; F, number of closed capillary rings; G, number of cell sprouts; H, MTS assay
showing cell proliferation in normoxic and hypoxic conditions, respectively. Data are expressed as mean ±SD of biological
triplicates. * P <0.05 vs normoxia associated cell type, ° P <0.05 vs CT normoxia, † P <0.05 vs wt normoxia, § P <0.05 vs CT
hypoxia, and ‡ P<0.01vs DN hypoxia; P value calculated using the Student t test. Bars in panel A, 10 µm. Each experiment was
performed in triplicate.
doi: 10.1371/journal.pone.0075538.g001
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talin and integin beta1 into lamellipodia during cell spreading
(Figure 4C and 4D) and at the leading edge of elongated-
moving cells, suggesting an involvement in the determination of
cell polarity.
Inhibition of Cdk5 activity with roscovitine resulted in a total
disorganisation of the actin- cytoskeleton and focal protein
localization (Figure 5). With roscovitine, pCdk5 (Figure 5A) and
p35 (Figure 5B) disassociated from actin filaments and stress
fibres, to form, with actin, cytoplasmic clumping and bundles.
Thus, p35 and Cdk5 activation seem essential for the
mechanisms of actin polymerization. Inhibition of Cdk5 in
Cdk5-DN mutant or roscovitine treated cells markedly
increased talin fragmentation (Figure 5) and reduced the
formation of focal talin tips (Figure 5C), preventing integrin
beta-1/talin bundling (Figure 5D).
Figure 2.  Cdk5 kinase activity is required for in vitro hBMECs angiogenesis.  Figure shows phase contrast images of in vivo
time course analysis of cell spreading (A), cell migration (B), and the formation of tubule like structure in roscovitine (50 µM) treated
(+) and untreated (-) cells (G). Graphs C and D report the computational analysis of the characterization of cell typologies during the
progression of different phases of cell spreading in controls (C) and roscovitine treated cells (D), determined using AnalyserTM
software. Compared to the controls (C), roscovitine (D) inhibited cell elongation and increased the time dependent cell distribution
between early and late spreading. Graphs E and F show the number of living and dividing cells presents in the wounded monolayer
area in controls (E) and with roscovitine treatment (F) determined using AnalyserTM software. (G) Representative time-lapse images
showing the progression of tubule formation throughout the time course, in controls and in treated cells. Graphs H and I, show the
relative quantitative evaluation of growth area in controls (H) and treated cells (I), determined by AnalyserTM software. (I) Roscovitine
reduced the growth area after 10h, mainly destabilizing neo-forming cell junctions and integrating cell networks. (L) Representative
images showing the inhibitory effect of roscovitine on sprout formation, compared to controls (-) and FGF-2 stimulated cells (positive
control). The phase contrast images have been acquired as z-stacks and with automated focusing. Bars, 20 µm. Original
magnification in L, x 200. Each experiment was performed in triplicate.
doi: 10.1371/journal.pone.0075538.g002
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Therefore, we hypothesised Cdk5/p35 to have a multipart
role where Cdk5 and p35 contribute to the mechanisms
inducing matrix/focal cytoskeletal stability and on the other
side, in those governing actin polymerization and
depolymerization, as required for cell traction and progression
of cell movement. In this scenario, p35 could be the/a stimulus
for F-actin fibre polymerization and polarity leading to the
formation of actin/focal plaque complexes. Inhibition of Cdk5
activity or reduced p35 content, as seen during hypoxia (Figure
S3) may reduce cell tension, and consequently affects
spreading architecture and in vitro migration.
Cdk5 and MEF2C promote proper spatial organization
of brain endothelial cells
The chaotic in vitro organization of EC tubule branches
observed in Cdk5-wt transfectants, prompted us to speculate
about the interplay of Cdk5 with other pathways involved in the
promotion of EC differentiation. Using an affymetrix microarray
(Figure S5) we analysed a cluster of genes involved in
angiogenesis and the potential impact of Cdk5 deregulation on
their expression. By Western blot analysis and co-
immunoprecipitation assays, we identified the myocyte
enhancer factor MEF2C (Figure S5), a transcription factor
involved in cell differentiation and angiogenesis, as a putative
Figure 3.  Cyto-architectural properties of Cdk5, activated Cdk5 (pCdk5) and p35.  (A) Representative image showing Cdk5
localization at the tip of actin fibre (arrow) in early spreading (Ai). (B) Panel showing pCdk5 (pTyr(Ser15)) localization with actin tips
(arrows) and fibre in early (Bi) and late (Bii) spreading and in moving (Biii) cells. (c) p35 co-localized with actin stress fibres and was
distributed from the nucleus (Ci) as the cell spreads culminating in filament tips (arrows in merge) in moving (Ciii) and late (Cii)
spreading cells. Immunofluorescence confocal microscope analysis. Objective 65x. Original magnification in merge, x 240. Bars, 25
µm. Original magnification in Ai merge, x 290. Original magnification in merge in panel A, x300. Each experiment was performed in
triplicate.
doi: 10.1371/journal.pone.0075538.g003
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molecular partner of Cdk5 in in vitro hBMEC/D3 angiogenesis
(Figure S5).
Moreover, blocking Cdk5 activity in Cdk5-DN, notably
reduced MEF2C protein levels and the opposite effect was
seen in Cdk5-wt (Figure S5). In control cells, MEF2C knock
down by siRNAs (Figure 6), reduced in vitro tubule formation
(Figure 6C) and cell sprouting (Figure 6E), but had only a
minor, non-significant effect on cell migration (Figure S6). In
view of that, we did not find any effect of MEF2C knock down
on actin fibre formation and/or on the co-localization of p35 with
talin (Figure S6C) in moving cells. This could suggest that in
hBMECs, MEF2C may be mainly required at the stage of
differentiation. Accordingly, we observed that in Cdk5-wt
(Figure 6C), MEF2C knockdown diminished the chaotic
organization of capillary tubule like structure, demonstrating
MEF2C as a Cdk5 molecular intermediate required to control
the proper time and spatial capillary network in hBMECs. This
interaction would likely take place at the nuclear level – since
both proteins were observed to co-localise in the nuclei (Figure
S5E).
Modulation of Cdk5/p25 signalling rescued in vitro
angiogenesis in acute hypoxia
The neuro-cytoprotective effect of CIP peptide has been
amply demonstrated during neurotoxic stress, wherein the
protection is conferred by the inhibition of Cdk5/p25 complex
formation [16]. Thus, we asked whether the introduction of this
peptide into brain ECs may prevent the detrimental effects
Figure 4.  pCdk5 and p35 cluster with integrin beta-1 and talin into the lamellipodias.  (A) Panel shows p35 clusters with talin
and integin beta-1 into lamellipodia during cell movement. Red arrows in merge-magnification show dots of integrin and talin co-
localisation. (B) Panel shows pCdk5 forming microvesicles with integrin beta-1 and talin at the lamellipodia in spreading cell. pCdk5
(C) and p35 (D) co-localized with talin in late spreading cells at focal tips (arrows in magnification). Immunofluorescent confocal
microscopical analysis. Ci and Di show negative control for the immunoco-staining IgG-488 (green), IgG-568 (red), IgG-460 (blue) in
Ci; and for the co-staining IgG-488 (green), IgG-568 (red), and DAPI (blue) in Di. Objective x40/x65. Original magnification in merge,
x 240. Bars, 25 µm. Each experiment was performed in triplicate.
doi: 10.1371/journal.pone.0075538.g004
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induced by hypoxia, possibly reducing the cleavage of p35 into
the more stable p25 peptide.
We found that CIP expression (Figure S7) was able to
rescue cell migration (Figure 7A) and the in vitro angiogenic
potential during hypoxia, increasing the capillarization (Figure
7B) and the formation of new sprouts (Figure 7C). At the
cytoskeletal level the organization of stress fibres with p35
clustering, which was de-regulated during hypoxia in control
cells (Figure 8Ai), was markedly stabilized (Figure 8Aii). This
was accompanied by an increased p35/p25 protein ratio
(Figure 8, C and D), indicating that CIP potentially can interfere
with/inhibit p35 cleavage induced by hypoxia (Figure S3C).
Notably, Cdk5 localization with actin fibres was only marginally
affected by hypoxia (Figure 8Bi) or in CIP transfectants (Figure
8 Bii). CIP vector insertion also demonstrated a positive in vitro
pro-angiogenic effect during normoxic conditions, promoting
cell migration (Figure S8) and increasing talin content,
specifically with production of a greater number of talin tips
containing p35 protein (Figure S9).
Discussion
Cdk5 hyper-activation mediated by the cleaved p35
fragment, p25, and initiated via calpains is crucially associated
Figure 5.  Blocking Cdk5 activity with roscovitine inhibited p35 and Cdk5 clustering with actin fibres and talin-integrin
beta-1 complex.  Inhibition of Cdk5 activity with roscovitine hampered co-localization of pCdk5 (panel A) and p35 (panel B) with
actin filaments and stress fibres, resulting in production of abnormal cytoplasmic bundles with actin (arrows in magnification) in early
spreading. (C) Roscovitine impaired the formation of talin tips and their co-localization with p35 and integrin beta-1. (D) Western blot
showing increased talin fragmentation (47kDa domain), in roscovitine treated cells.
Calculated results are reported in graphs: E, level of talin protein fragmentation in untreated cells and with roscovitine treatment; F,
protein level of talin large domain (235kDa) in untreated and roscovitine treated cells. Data are expressed as mean ±SD of
biological triplicates. * P <0.05. P value calculated using the Student t test. Immunofluorescence confocal analysis, objective 65x.
Bars, 25 µm. Original magnification, x 200. Original magnification in merge Bii, x 230. Each experiment was performed in triplicate.
doi: 10.1371/journal.pone.0075538.g005
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with neuronal cytoskeletal derangement, neuronal apoptosis
and cell death during ischemic brain insult [9], while activation
of Cdk5 through the parent p35 is associated with
cytoprotection [11]. Cdk5 and p35/p25 are concomitantly
overexpressed in ECs in hypoxic regions of stroke tissue [10],
suggesting that the balance of signaling between these
pathways may help to define cellular fate in relation to
angiogenesis or cell protection after stroke [13]. Our study
demonstrates that Cdk5 activation through its major substrate
p35 provides a key trigger for initiation and maintenance of in
vitro brain EC angiogenesis and that this interaction and
signalling cascade is crucial for ensuring correct cytoskeletal
organisation/dynamics, involving integrin beta-1 and talin, and
allowing cell spreading and subsequent cell migration.
Operating via the novel binding partner, nuclear transcription
factor MEF2C, angiogenesis in vitro proceeds with cell
differentiation and tube-like-structure formation. Our results
also show that introducing a natural inhibitor of p25/Cdk5
complex formation, the CIP peptide [16], we were able to alter
the balance of p25/p35-Cdk5 signalling in favour of p35 and
concomitantly and significantly increase in vitro brain EC
angiogenesis during normoxia and most importantly, promoting
cell survival and capillarisation in hypoxic conditions.
Figure 6.  Cdk5 and MEF2C promote proper spatial organization of brain endothelial cells.  Figure shows the effect of MEF2C
knock down, using siRNAs on angiogenesis in control cells (CT) and Cdk5-wt transfectants (wt). Scrambled siRNA has been used
as negative controls. (A) Western blot analysis showing the effect of siRNA on MEF2C protein levels in wt cells. (B) siRNA reduced
MEF2C protein expression by approximately 80%. (C) Tubule network (24h) was inhibited in control cells, while appeared more
structured in Cdk5-wt transfectants. Nonetheless, the number of complete closed rings (D) was significantly reduced in both controls
and Cdk5-wt transfectants as the spheroid sprout length and thickness (E) or sprouts number (F). Calculated results are reported in
graphs: B, MEF2C protein levels (as ration on GAPDH OD) in wt and siMEF2C, or scrambled wt transfected cells; D, number of
closed capillary ring structure determined on Matrigel® assay; F, number of cell sprouts determined in spheroid assay. Data are
expressed as mean ± SD of biological triplicates. For all figures * P <0.05 vs controls. P value calculated using the Student t test.
Phase contrast images; bars, 20 µm; bars in panel C, 50 µm. Experiments were performed in triplicate.
doi: 10.1371/journal.pone.0075538.g006
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Several studies in animal and in vitro models have described
important functions of the myogenic transcriptional effector
MEF2C, a crucial pro-survival protein, during vascular
development, vasculogenesis and angiogenesis [30,31].
Targeted deletion of the MEF2C gene in mice, results in
embryonic lethality with significant cardiovascular defects and
severe vascular abnormalities, wherein endothelial cells retain
the capability to differentiate but are unable to organize into a
functional vascular network [32]. Here, we found a significant
association between MEF2C protein levels and degree of in
vitro angiogenesis using both Cdk5-wt and DN-kinase mutant
transfectants. An increase in MEF2C expression in Cdk5-wt
resulted in abnormal and chaotic vascular network production,
higher levels of cellular migration and longer but thinner
spheroid–sprout lumens. In contrast, the reduced amount of
MEF2C seen in DN-kinase mutants was coupled with
significantly reduced and disorganised EC spatial organisation.
Figure 7.  CIP-vector peptide rescues in vitro angiogenesis in hypoxia.  (A) Panel reports a representative image of the effect
of CIP–vector peptide on hBMECs cell migration during hypoxia (ii), versus controls in normoxia (iv), detected by phase contrast
time-lapse analysis. (B,C) Representative contrast phase microscopy images of the effect of CIP–vector peptide on hBMECs tubule
formation (B) and spheroid cell sprouting (C) in normoxic (i) and hypoxic conditions (ii). As Cdk5-wt CIP insertion significantly
promoted cell migration during hypoxia, (D). (E) In CIP transfectants, the number of complete closed rings was significantly
increased during normoxia (Bi), and maintained during hypoxia (Bii). Compared to the controls and Cdk5-wt, CIP insertion promoted
the formation of spheroid–sprouts, which appeared with thicker lumens (C) and increased in number (F) in both hypoxic or normoxic
conditions. Calculated results vs. controls and EV are reported in graphs: D, number of migrated cells in wound area during hypoxia,
determined by AnalyserTM software; E, number of closed capillary ring structures on Matrigel® assay; F, number of cell sprouts in
spheroid assay. Data are expressed as mean ±SD of biological triplicates. For all figures * P <0.05, and ° P <0.01. P value
calculated using the Student t test. The phase contrast images of migration assay have been acquired as z-stacks and with
automated focusing. Bars, 20µm; bars panel C, 50 µm. Bars, panel A 20 µm; panel B, 50 µm; 20 µm in panel C. Each experiment
was performed in triplicate.
doi: 10.1371/journal.pone.0075538.g007
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Knockdown of MEF2C using small-interfering RNAs in Cdk5-
wt, re-established the proper cellular network, whilst reducing
abnormal cell migration and sprouting. In non-transfected cells
MEF2C knockdown blocked almost completely the formation of
neo-capillaries, suggesting that MEF2C could be an important
Cdk5-signalling intermediate in brain ECs, and a key
requirement for functional in vitro angiogenesis. A relationship
between Cdk5 and MEF2C in angiogenesis has not been
reported previously. However, Cdk5/p25 complexes have been
shown to phosphorylate other members of MEF2 family
(MEF2A and MEF2D), inhibiting their pro-survival activity,
through a caspase-3 dependent degradation, in response to
neurotoxic stress [33,34], without show any targeting on
MEF2C [33]. Notably, restoration of the active form of MEF2
has been proved to be protective following focal ischemia [35]
and increasing MEF2 phosphorylation levels (ser59) has been
recently described in rat brain ischemic stroke models after
inhibition of calpain/Cdk5/p25 signalling, by sildenafil, used to
antagonise chemical hypoxia induced by malonate [12].
Here, using a protein pull down assay, we were able to co-
immunoprecipitate the two proteins, but whether this
association may be due to a regulatory mechanism on MEF2C
stability mediated by Cdk5 phosphorylation is still to be defined.
Further work should investigate whether Cdk5 is acting as a
Figure 8.  CIP-vector peptide preserves p35/actin intracellular co-localization during hypoxia.  (A) Images show the effect of
hypoxia on p35 (left panel, Ai) and Cdk5 (right panel, Bi) intracellular distribution with actin filaments and fibres in hBMECs. Under
hypoxia, p35 (Ai) lost its canonical filament-like structure organization (in merge, upper left panel) and localization at actin fibre tips,
showing a more diffuse cytoplasmic distribution, while Cdk5 (Bi) maintained its co-localization with actin fibre tips (arrows in merge,
upper right panel) (ii). Compared to the controls CIP insertion protected p35 (Aii) and Cdk5 (Bii) intracellular localization with actin
filaments and fibres from the effects of hypoxia, this was associated with increased p35 protein contents (C) and increased p35/p25
protein ratio (D). Calculated results are reported in graph D; optical density (OD) of p35/p25 protein ratio in control untransfected
cells and in CIP transfectants determined in normoxic and hypoxic conditions. Typical images from n=2 independent experiments.
Immunofluorescence confocal analysis; bars, 20 µm. Original magnification, x 100. Each experiment was performed in triplicate.
doi: 10.1371/journal.pone.0075538.g008
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direct regulator of MEF2C gene expression, perhaps via the
E2F1-pRb axis [36,37].
Published work has demonstrated non-nuclear functions
linked to Cdk5 in the regulation of cytoskeleton dynamic and
motility [5], showing Cdk5 as a key modulator of talin stability
and therefore essential to cell migration [38]. Thus, we
investigated the interplay of Cdk5 and p35 with classical
molecular players of the control of mechanical forces and
motility. We found a specific time/spatial interaction of active
(phosphorylated) p-Cdk5 and p35 with integrin beta-1 and talin,
directed to the formation of microvesicles in late-spreading and
elongated/moving cells. Accordingly with previous observations
[5,39,40], p35, Cdk5 and pCdk5 localized at the focal tips of
actin stress fibres. Inhibition of this interaction, by roscovitine or
in DN-mutants blocked in our cellular model, cell protrusion and
stable adhesions. Notably, we found that p35 localization
alongside actin fibres during spreading is time-dependent and
culminates with the formation of focal clusters with Cdk5,
integrin beta-1 and talin. On this basis, we hypothesised that
p35 may be a putative adaptor implicated in the generation of
cellular tension. The association of p35 with talin and integrin
beta-1 may result in the formation of a molecular bridge among
cytoplasmic domains of integrins and actin fibres [38]. p35-
mediated activation of Cdk5 at that sites, in conjunction with
talin, may be required for activation/phosphorylation of integrins
and to the resulting actin polarised organization [40]. Hence,
we suggest that the formation of p35 complexes with pCdk5 at
focal adhesion points may relate to Cdk5 activation at focal-
regions and be involved in integrins kinase/activation.
In our study, hypoxia markedly impaired in vitro
angiogenesis, leading to a noticeable alteration in stress fibre
cyto-structure with delocalization of p35 from these fibres. This
was reflected in a marked inhibition of cell spreading and
migration. These changes were associated with decreased p35
expression and a parallel increase in calpain expression and in
the cleavage product p25. Notably, modulating Cdk5/p35
activation with the novel natural inhibitor of p25/Cdk5 complex,
the CIP- peptide, we were able to reduce p35 cleavage to p25
and ameliorate angiogenesis during in vitro hypoxia. CIP
increased recovery of cell spreading and formation of stable
neo-capillaries, potentially increasing p35 localization with actin
fibres and therefore the stabilization of the actin cytoskeleton.
On this base, we propose that p35/cdk5 signalling elicits a
specific protective role during in vitro angiogenesis and
together with the observed protective action of the CIP peptide,
may potentially aid in tissue remodelling after ischaemic stroke.
In conclusion, our results show that the p35/Cdk5 is a
pathway that is critically involved in controlling cell dynamics of
brain EC. Activation of p35/Cdk5 signalling at the expense of
p25-Cdk5 plays a protective role in hypoxic conditions, and
positively contributes to preserve cell motility and the proper
spatial and temporal control of cytoskeletal dynamics, which is
essential for successful angiogenesis.
Supporting Information
Figure S1.  R-roscovitine selectively inhibited Cdk5 activity
and tyrosine phosphorylation: (A-B) Inhibition of histone
phosphorylation; (C-E) Cdk5 phosphorylation but not that
of Cdk2. Each experiment was performed in triplicate.
(TIF)
Figure S2.  R-roscovitine was not cytotoxic to hBMECs at
concentrations used: (A-B) no increase in propidium
Iodide inclusion was found, whilst (C-D) neither p-53 nor
caspase-3 activity increased. (E) No reduction in cell number
was seen in proliferation assays up until 70 µM concentration
of R-roscovitine. All experiments were performed three times.
(TIF)
Figure S3.  In vitro hypoxia induced cell damaging effects
in hBMECs: (A and D) increased Propidium Iodide nuclear
inclusion; (B) increased expression of Hsp70; (B-C)
increased p-35 protein cleavage and more p25 expression;
(E) an increase in calpain expression, and (F-G) an
increase in the ratio of p25/p35. All experiments were carried
out three times.
(TIF)
Figure S4.  R-roscovitine inhibited, spreading, migration
and tube formation of hBMECs: (Ai and C) R-roscovitine
showed a reduced number of cells with the capacity to
elongate as well as closure in a scratch wound assay (Aii
and D) and form closed tube-like structures (Aiii and E).
Numbers of cells attaching in cell culture plates was also
significantly reduced (B). All experiments were repeated three
times.
(TIF)
Figure S5.  Gene microarray studies identified MEF2C
down-regulation in Cdk5-DN mutants: (A) gene array
results with Western blot confirmation of MEF2C protein
down-regulation in DN mutants (B-C); (D)
immunoprecipitation showing direct intracellular binding
of Cdk5 with MEF2C protein and (E), double
immunoflourescent labelling demonstrating MEF2C co-
localization with phospho-Cdk5. All experiments were
repeated three times.
(TIF)
Figure S6.  siRNA down-regulation of MEF2C inhibited
hBMEC angiogenesis and talin-p35 co-localization in
spreading cells: (A-B) siRNA to MEF2C significantly
inhibited hBMEC migration in the scratch wound assay;
(C) double immunoflourescent labelling showed notably
reduced talin-p35 protein interaction at the tips of
spreading cells concomitant with reduced ability to
polarise and spread. All experiments were performed three
times.
(TIF)
Figure S7.  CIP transfectants expressed higher levels of
CIP peptide: (A) immunofluorescent identification of CIP-
GFP cellular uptake; (B-C) CIP transfectants e.g. CIP14 and
CIP 17 expressed notably more peptide.
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(TIF)
Figure S8.  Effect of CIP transfection on hBMEC wound
healing: (A-B) The presence of CIP-vector inside hBMEC
significantly increased wound closure/migration compared
with empty vector/control cells. Experiments were repeated
three times.
(TIF)
Figure S9.  (TIF)
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